Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRA2A | P08913 | 18/20 | 0.60 |
| ▸ | ADRA2B | P18089 | 18/20 | 0.60 |
| ▸ | ADRA2C | P18825 | 18/20 | 0.60 |
| ▸ | PTGIR | P43119 | 1/20 | 0.58 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.48 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.48 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1036359 | 0.87 | ADRA2A (0.78) | ADRA2AADRA2BADRA2CPTGIRADRA1D | |
| SCHEMBL11180468 | 0.84 | ADRA2A (0.85) | ADRA2AADRA2BADRA2CPTGIRADRA1D | |
| Benzophenone SCHEMBL5084127 | 0.79 | ADRA2A (0.80) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL11283477 | 0.77 | ADRA2A (0.61) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL13017193 | 0.77 | ADRA2A (0.88) | ADRA2AADRA2BADRA2CPTGIRADRA1D | |
| SCHEMBL4687421 | 0.74 | ADRA2A (0.70) | ADRA2AADRA2BADRA2CPTGIR | |
| Diphenylamine SCHEMBL329810 | 0.74 | ALDH1A1 (0.70) | — | |
| SCHEMBL5803227 | 0.74 | ADRA2A (0.88) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL11163847 | 0.74 | ADRA2A (0.88) | ADRA2AADRA2BADRA2CPTGIR | |
| SCHEMBL5802197 | 0.74 | PTGIR (1.00) | ADRA2AADRA2BADRA2CPTGIR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080194666-A1 | Combination Treatment Methods | MEDICAL RESEARCH COUNCIL (GB) | 2008-08-14 | — | — | US | claimed |
| WO-2006106311-A2 | COMBINATION TREATMENT METHODS FOR TREATING SEX-HORMONE DEPENDENT DISEASE AND FERTILITY TREATMENT | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2006-10-12 | — | — | WO | claimed |
| US-20060171945-A1 | Ip receptor antagonists for the treatment of pathological uterine conditions | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH, THE (GB) | 2006-08-03 | — | — | US | claimed |
| EP-1596858-A1 | IP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PATHOLOGICAL UTERINE CONDITIONS | Medical Research Council (GB) | 2005-11-23 | — | — | EP | claimed |
| WO-2004071508-A1 | IP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PATHOLOGICAL UTERINE CONDITIONS | MEDICAL RESEARCH COUNCIL (GB) | 2004-08-26 | — | — | WO | claimed |
| US-9321745-B2 | Inhibition of neovascularization by inhibition of prostanoid IP receptors | ALLERGAN, INC. (US) | 2016-04-26 | — | — | US | disclosed |
| US-9295665-B2 | Inhibition of neovascularization by simultaneous inhibition of prostanoid IP and EP4 receptors | ALLERGAN, INC. (US) | 2016-03-29 | — | — | US | disclosed |
| WO-2014143591-A9 | INHIBITION OF NEOVASCULARIZATION BY SIMULTANEOUS INHIBITION OF PROSTANOID IP AND EP4 RECEPTORS | ALLERGAN, INC. (US) | 2014-10-16 | — | — | WO | disclosed |
| WO-2014143592-A1 | INHIBITION OF NEOVASCULARIZATION BY INHIBITION OF PROSTANOID IP RECEPTORS | ALLERGAN, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275200-A1 | INHIBITION OF NEOVASCULARIZATION BY SIMULTANEOUS INHIBITION OF PROSTANOID IP AND EP4 RECEPTORS | ALLERGAN, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2014143591-A1 | INHIBITION OF NEOVASCULARIZATION BY SIMULTANEOUS INHIBITION OF PROSTANOID IP AND EP4 RECEPTORS | ALLERGAN, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140275238-A1 | INHIBITION OF NEOVASCULARIZATION BY INHIBITION OF PROSTANOID IP RECEPTORS | ALLERGAN, INC. (US) | 2014-09-18 | — | — | US | disclosed |
| WO-2006106311-A2 | COMBINATION TREATMENT METHODS FOR TREATING SEX-HORMONE DEPENDENT DISEASE AND FERTILITY TREATMENT | MEDICAL RESEARCH COUNCIL TECHNOLOGY (GB) | 2006-10-12 | — | — | WO | disclosed |
| US-20060171945-A1 | Ip receptor antagonists for the treatment of pathological uterine conditions | UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH, THE (GB) | 2006-08-03 | — | — | US | disclosed |
| EP-1596858-A1 | IP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PATHOLOGICAL UTERINE CONDITIONS | Medical Research Council (GB) | 2005-11-23 | — | — | EP | disclosed |
| WO-2004071508-A1 | IP RECEPTOR ANTAGONISTS FOR THE TREATMENT OF PATHOLOGICAL UTERINE CONDITIONS | MEDICAL RESEARCH COUNCIL (GB) | 2004-08-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140275200-A1 | INHIBITION OF NEOVASCULARIZATION BY SIMULTANEOUS INHIBITION OF PROSTANOID IP AND EP4 RECEPTORS | PTGIR, PTGER4, PTGIS | ADRA2A 324/4885ADRA2B 231/4885ADRA2C 779/4885 |
| US-20080194666-A1 | Combination Treatment Methods | GNRHR, SHBG, FSHR | ADRA2A 632/4885ADRA2B 806/4885ADRA2C 1127/4885 |
| US-20140275238-A1 | INHIBITION OF NEOVASCULARIZATION BY INHIBITION OF PROSTANOID IP RECEPTORS | PTGIR, PTGIS, PTGFR | ADRA2A 179/4885ADRA2B 135/4885ADRA2C 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.